Our in silico analysis confirmed the implication of miR-27a in the SLE pathway by targeting several genes coding for variable histone family proteins, RNA-binding proteins, and several immune-response-related proteins, such as HLA class II histocompatibility antigen and CD28, which can modulate antigen processing and presentation by immune cells, autoantigen production, and the clearance mechanism, as depicted in Figure 8. The gene discussed is CD28; the disease is systemic lupus erythematosus.